reports
- Maxim Jacobs
Therapix Biosciences - Two new cannabinoid programs
Therapix is expanding its cannabinoid-based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a chronic sleep disorder. The company is investigating the efficacy of THX-OSA01, an oral THC/PEA formulation, for the treatment of OSA in a 30-patient Phase IIa trial. In addition, Therapix is exploring the potential of a cannabinoid composition containing an antibacterial agent for the treatment of infectious diseases in preclinical trials. The company...
- Maxim Jacobs
Tackling neurology with cannabinoids
Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline appro...
- Maxim Jacobs
Cannabinoids for underserved diseases
Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The lead clinical program, THX-TS01, is a combination of THC, the primary active ingredient in cannabis, and palmitoylethanolamide, a molecule generally regarded as safe, which is approved for use as a health supplement in some parts of Europe and Canada. THX-TS01 is currently in Phase II trials testing its potential for treating Tourette’s in adults. The...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.